Holen Sie sich die Stockscreener-App
0.3646
8.71%
-0.0348
Immunoprecise Antibodies Ltd Aktie (IPA) Neueste Nachrichten
ImmunoPrecise Q3 Earnings Postponed: Auditors Request Extra Time for Goodwill Review - StockTitan
ImmunoPrecise Antibodies Reschedules Q3 Financial Results Release - TipRanks
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 | FinancialContent - Financial Content
Immunoprecise Antibodies Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Short Interest Update - Defense World
ImmunoPrecise Antibodies (IPA) to Release Earnings on Thursday - Defense World
ImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery - ACCESS Newswire
ImmunoPrecise Antibodies to Announce Q3 Fiscal 2025 Results - TipRanks
AI Antibody Pioneer ImmunoPrecise Sets March 13 Earnings CallWhat's Next for This Biotech Innovator? - StockTitan
ImmunoPrecise Antibodies Ltd. (IPA) Expands AI Leadership with Dr. Kamil Isaev Appointment - Insider Monkey
IPA and Ribopro form mRNA antibody discovery collaboration - Yahoo Finance
ImmunoPrecise Antibodies appoints Joseph Scheffler interim CFO - MSN
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy - 01Net
ImmunoPrecise & RIBOPRO Partner for AI-Powered Antibody Discovery - Contract Pharma
ImmunoPrecise Antibodies and RIBOPRO Partner to Revolutionize Antibody Discovery - TipRanks
ImmunoPrecise Antibodies annonce un remaniement de son équipe de direction - The Hastings Tribune
ImmunoPrecise Antibodies Announces Key Leadership Changes - Business Wire
AI Pioneer Joins ImmunoPrecise Board: Can New Leadership Accelerate Biotech Innovation? - StockTitan
ImmunoPrecise Antibodies Transfers to Nasdaq Capital Market, Gains Extension - TipRanks
Immunoprecise Antibodies Announces Transfer To Nasdaq Capital Market And Extension Of Bid Price Compliance Period - Marketscreener.com
ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period - Business Wire
ImmunoPrecise Antibodies Ltd (IPA) Shares Up Despite Recent Market Volatility - The News Heater
Check Out ImmunoPrecise Antibodies Ltd (IPA)’s Trade Data Rather Than the Analysts’ Views - SETE News
ImmunoPrecise Antibodies Ltd (IPA) presents a great opportunity, but the stock is slightly overvalued - US Post News
ImmunoPrecise Antibodies Boosts Financial Position Through Successful Capital Initiatives - TipRanks
ImmunoPrecise Antibodies (OTCMKTS:IPATF) Shares Down 3.9% – Here’s Why - Defense World
ImmunoPrecise Antibodies Ltd. (IPA) Unveils AI-Developed GLP-1 Therapies for Type 2 Diabetes and Obesity, Pioneering New Frontiers in Biotech Innovation - Insider Monkey
ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture - The Globe and Mail
ImmunoPrecise Antibodies Strengthens Financial Position with Strategic Capital Initiatives - TipRanks
ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology - ACCESS Newswire
Benchmark maintains Buy on Immunoprecise stock, target at $3.00 - MSN
Benchmark maintains Buy on Immunoprecise stock, target at $3.00 By Investing.com - Investing.com Canada
Immunoprecise uses AI to develop new class of GLP-1 therapies - BioWorld Online
ImmunoPrecise Antibodies develops new class of GLP-1 therapies through AI - Yahoo Finance
Stock Traders Buy High Volume of ImmunoPrecise Antibodies Call Options (NASDAQ:IPA) - Defense World
What's Going On With ImmunoPrecise Antibodies Stock Wednesday? - Benzinga
S&P 500 Growth (IGX) QuotePress Release - The Globe and Mail
TSX Renewable and Clean Tech Index (TXCT) QuotePress Release - The Globe and Mail
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX Global Mining Index (TXGM) QuotePress Release - The Globe and Mail
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therap - GuruFocus.com
ImmunoPrecise Antibodies Leverages AI for Next-Gen Diabetes Treatment - TipRanks
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment - Business Wire
ImmunoPrecise Antibodies Ltd. (IPA) Launches AI-Powered Drug Discovery Pipeline, Revolutionizing Therapeutic Development with LENSai™ Platform - Insider Monkey
10 Trending AI Stocks on Latest News and Ratings - Insider Monkey
ImmunoPrecise launches AI-driven drug discovery pipeline - Investing.com India
ImmunoPrecise launches AI-driven drug discovery pipeline By Investing.com - Investing.com Canada
ImmunoPrecise Antibodies Launches AI-Powered Drug Discovery Platform - TipRanks
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation - Business Wire
Even With A 30% Surge, Cautious Investors Are Not Rewarding ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Performance Completely - Simply Wall St
ImmunoPrecise Launches Groundbreaking AI Platform LENSai for Revolutionary Drug Discovery - StockTitan
2.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):